/
NBTX
$35.96-$0.03 (-0.08%)live
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Market cap
$1.8B
51M shares
52-week range
$4.57 – $57.14
60% from low
Exchange
NASDAQ
ADRC
Borrow rate
101.19%
Hard to borrow
Price (6 mo)
Loading chart…
Change+$22.18
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $3.5M | $2.5M | $2.3M | $2.6M | $4.8M | $36.2M | −$7.2M | $29.6M |
| Cost of revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Gross profit | $3.5M | $2.5M | $2.3M | $2.6M | $4.8M | $36.2M | −$7.2M | $29.6M |
| Gross margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| R&D | $20.9M | $30.4M | $24.3M | $30.4M | $32.6M | $38.4M | $40.5M | $23.1M |
| Operating income | −$30.1M | −$46.8M | −$36.4M | −$52.6M | −$46.7M | −$26.8M | −$68.4M | −$10.8M |
| EBITDA | −$29.4M | −$45.0M | −$34.9M | −$45.6M | −$44.2M | −$23.7M | −$67.7M | −$12.1M |
| Net income | −$30.3M | −$50.9M | −$33.6M | −$47.0M | −$57.0M | −$39.7M | −$68.1M | −$24.0M |
| Net margin | -872.2% | -2003.7% | -1444.7% | -1775.7% | -1194.3% | -109.6% | 947.6% | -80.8% |
| EPS (diluted) | -1.52 | -2.35 | -1.38 | -1.35 | -1.64 | -1.08 | -1.44 | -0.50 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $34M | $-0.20 | $-0.82–$0.62 | 3 |
| 2027 | $58M | $-0.08 | $-0.21–$0.07 | 3 |
| 2028 | $95M | $0.47 | $0.29–$0.68 | 1 |
| 2029 | $97M | $0.57 | $0.35–$0.84 | 1 |
Forward consensus · source: Financial Modeling Prep
Peer comparison
Nanobiotix S.A. American Depositary Shares
Nanobiotix SA is a late-stage clinical biotechnology company focused on re-inventing medicine by building new therapies atom by atom, developing widely applicable, first-in-class, physics-based nanotherapeutics to transform treatment outcomes and expand life for millions of patients. The objective of this physics-based approach is to allow nanoparticles to be combined with other drugs or therapeutic modalities and to integrate seamlessly into clinical practice without adding burden for the patient, healthcare provider, or healthcare system. It has three platforms Nanoradioenhancer platform: Nanoprimer platform: and Neurological disease platform. It has one segment, which is the research and development of product candidates that use proprietary nanotechnology to transform cancer treatment.
www.nanobiotix.com- Employees
- 97
- IPO / List date
- Dec 11, 2020
Held by traders on TradeandTell
No one on the platform currently holds NBTX.
Super investors & insiders
Institutions holding (13F)
No tracked institution reports a position in NBTX as of their last filing.
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded NBTX yet.
